BMNDF.US Biomind Labs Inc.

Healthcare Biotechnology USA Stocks
0.2153 USD
Close of Nov 13, 2026
0.0110 0.8000
Market cap
USD 16.7M
P/E
-
P/B
183.79x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BMNDF.US undervalued?

Graham number

The Graham number of Biomind Labs Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biomind Labs Inc. fundamental analysis

No fundamental analysis for Biomind Labs Inc. yet.

Biomind Labs Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biomind Labs Inc.

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's dis…

Full company profile